Eli Lilly has claimed FDA approval for its IL-23 inhibitor Omvoh as a treatment for moderately to severely active Crohn's disease, extending its use beyond ulcerative colitis (UC) for the first time.

LLY's blockbuster obesity drugs fuel rapid growth but ABBV's valuation and pipeline may offer safer short-term upside.

Recent approvals in immunology (Omvoh and Ebglyss), oncology (Jaypirca) and neuroscience (Kisunla) highlight Lilly’s intent to diversify beyond obesity and diabetes.

Lilly’s emphasis on patient-reported outcomes (PROs) has differentiated Omvoh from its competitors, and the company will further its case at ECCO 2025 by unveiling results from the LUCENT-URGE ...

Novo Nordisk NVO and Eli Lilly LLY dominate the diabetes and obesity market on the back of the tremendous success of their ...

Lilly expects its new drugs, Mounjaro, Zepbound, Omvoh, Jaypirca, Ebglyss and Kisunla, along with the expanded use of existing drugs, to drive sales growth in 2025.

A high-level overview of Eli Lilly and Company (LLY) stock. View (LLY) real-time stock price, chart, news, analysis, analyst reviews and more.

He added that ACG recommends IL-23 inhibitors like mirikizumab (Omvoh, Eli Lilly & Co.), guselkumab (Tremfya, Johnson & Johnson) and risankizumab (Skyrizi, AbbVie) for induction and maintenance of ...

Verve Therapeutics VERV signed a definitive agreement with pharma bigwig Eli Lilly LLY. Per the terms, the pharma giant will acquire all outstanding shares of VERV for $10.50 per share in cash, ...

Shares of companies that pay reliable dividends can typically be bought and held forever. These five have paid dividends for 100 years.